DENTSPLY SIRONA Croissance future
Future contrôle des critères 3/6
DENTSPLY SIRONA devrait augmenter ses bénéfices et son chiffre d'affaires de 73.9% et de 1.2% par an respectivement. Le BPA devrait croître de de 77.1% par an. Le rendement des capitaux propres devrait être 16.6% dans 3 ans.
Informations clés
73.9%
Taux de croissance des bénéfices
77.1%
Taux de croissance du BPA
| Medical Equipment croissance des bénéfices | 17.1% |
| Taux de croissance des recettes | 1.2% |
| Rendement futur des capitaux propres | 16.6% |
| Couverture par les analystes | Good |
| Dernière mise à jour | 11 Nov 2024 |
Mises à jour récentes de la croissance future
Recent updates
DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Looks Inexpensive After Falling 27% But Perhaps Not Attractive Enough
Nov 11
DENTSPLY SIRONA (NASDAQ:XRAY) Hasn't Managed To Accelerate Its Returns
Oct 13DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Looks Inexpensive But Perhaps Not Attractive Enough
Sep 25Is It Time To Consider Buying DENTSPLY SIRONA Inc. (NASDAQ:XRAY)?
Sep 05Is There An Opportunity With DENTSPLY SIRONA Inc.'s (NASDAQ:XRAY) 21% Undervaluation?
Aug 18Returns On Capital At DENTSPLY SIRONA (NASDAQ:XRAY) Have Hit The Brakes
Jul 11A Tough Macro Environment Makes Dentsply Sirona's Turnaround Even Harder
Jul 02Insufficient Growth At DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Hampers Share Price
Jun 11We Think DENTSPLY SIRONA (NASDAQ:XRAY) Can Stay On Top Of Its Debt
May 24Dentsply Sirona: I'm Buying The Pullback In This Medtech Leader
Apr 24Are Investors Undervaluing DENTSPLY SIRONA Inc. (NASDAQ:XRAY) By 47%?
Apr 22There's No Escaping DENTSPLY SIRONA Inc.'s (NASDAQ:XRAY) Muted Revenues
Mar 10Here's Why DENTSPLY SIRONA (NASDAQ:XRAY) Has A Meaningful Debt Burden
Feb 16DENTSPLY SIRONA (NASDAQ:XRAY) Has More To Do To Multiply In Value Going Forward
Jan 29DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Shares Could Be 28% Below Their Intrinsic Value Estimate
Jan 11Is It Too Late To Consider Buying DENTSPLY SIRONA Inc. (NASDAQ:XRAY)?
Nov 25These 4 Measures Indicate That DENTSPLY SIRONA (NASDAQ:XRAY) Is Using Debt Extensively
Nov 06Returns On Capital At DENTSPLY SIRONA (NASDAQ:XRAY) Paint A Concerning Picture
Oct 15An Intrinsic Calculation For DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Suggests It's 46% Undervalued
Sep 18DENTSPLY SIRONA (NASDAQ:XRAY) Has A Pretty Healthy Balance Sheet
Jul 31The Returns At DENTSPLY SIRONA (NASDAQ:XRAY) Aren't Growing
Jul 09A Look At The Fair Value Of DENTSPLY SIRONA Inc. (NASDAQ:XRAY)
Jun 20When Should You Buy DENTSPLY SIRONA Inc. (NASDAQ:XRAY)?
Jun 02Investors Don't See Light At End Of DENTSPLY SIRONA Inc.'s (NASDAQ:XRAY) Tunnel
May 15The Returns At DENTSPLY SIRONA (NASDAQ:XRAY) Aren't Growing
Apr 05Is DENTSPLY SIRONA (NASDAQ:XRAY) Using Too Much Debt?
Mar 07We Think DENTSPLY SIRONA (NASDAQ:XRAY) Can Stay On Top Of Its Debt
Nov 09Dentsply Sirona names Glenn Coleman as new CFO
Sep 22Dentsply Sirona hires Simon Campion as president, CEO
Aug 25Dentsply Sirona receives noncompliance notice from Nasdaq
Aug 16Dentsply Sirona: Weakening Fundamentals Outweigh 'Defensives' Argument
Jul 18Prévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 12/31/2026 | 3,907 | 219 | 368 | N/A | 12 |
| 12/31/2025 | 3,786 | 170 | 323 | 497 | 14 |
| 12/31/2024 | 3,813 | -437 | 310 | 524 | 13 |
| 9/30/2024 | 3,900 | -413 | 365 | 534 | N/A |
| 6/30/2024 | 3,896 | -185 | 364 | 527 | N/A |
| 3/31/2024 | 3,940 | -95 | 279 | 423 | N/A |
| 12/31/2023 | 3,965 | -132 | 228 | 377 | N/A |
| 9/30/2023 | 3,936 | -214 | 218 | 359 | N/A |
| 6/30/2023 | 3,936 | -1,025 | 198 | 334 | N/A |
| 3/31/2023 | 3,931 | -1,038 | 259 | 403 | N/A |
| 12/31/2022 | 3,922 | -950 | 368 | 517 | N/A |
| 9/30/2022 | 4,042 | -816 | 439 | 597 | N/A |
| 6/30/2022 | 4,135 | 345 | 499 | 660 | N/A |
| 3/31/2022 | 4,174 | 368 | 545 | 701 | N/A |
| 12/31/2021 | 4,231 | 411 | 515 | 657 | N/A |
| 9/30/2021 | 4,207 | 401 | 584 | 712 | N/A |
| 6/30/2021 | 4,062 | 370 | 634 | 748 | N/A |
| 3/31/2021 | 3,491 | 179 | 617 | 708 | N/A |
| 12/31/2020 | 3,339 | -73 | 562 | 649 | N/A |
| 9/30/2020 | 3,371 | -80 | 575 | 672 | N/A |
| 6/30/2020 | 3,438 | -48 | 524 | 623 | N/A |
| 3/31/2020 | 3,957 | 84 | 479 | 594 | N/A |
| 12/31/2019 | 4,022 | 256 | 516 | 639 | N/A |
| 9/30/2019 | 3,977 | 162 | 397 | 536 | N/A |
| 6/30/2019 | 3,944 | 105 | 337 | 502 | N/A |
| 3/31/2019 | 3,976 | -1,053 | 291 | 474 | N/A |
| 12/31/2018 | 3,986 | -1,011 | 312 | 500 | N/A |
| 9/30/2018 | 4,018 | -1,663 | 345 | 527 | N/A |
| 6/30/2018 | 4,098 | -1,601 | N/A | 565 | N/A |
| 3/31/2018 | 4,049 | -1,529 | N/A | 575 | N/A |
| 12/31/2017 | 3,993 | -1,550 | N/A | 602 | N/A |
| 9/30/2017 | 3,899 | -793 | N/A | 595 | N/A |
| 6/30/2017 | 3,844 | -791 | N/A | 584 | N/A |
| 3/31/2017 | 3,873 | 365 | N/A | 645 | N/A |
| 12/31/2016 | 3,745 | 430 | N/A | 563 | N/A |
| 9/30/2016 | 3,420 | 382 | N/A | 467 | N/A |
| 6/30/2016 | 3,115 | 374 | N/A | 474 | N/A |
| 3/31/2016 | 2,791 | 312 | N/A | 433 | N/A |
| 12/31/2015 | 2,674 | 251 | N/A | 497 | N/A |
| 9/30/2015 | 2,722 | 277 | N/A | 564 | N/A |
| 6/30/2015 | 2,782 | 268 | N/A | 551 | N/A |
| 3/31/2015 | 2,849 | 314 | N/A | 561 | N/A |
| 12/31/2014 | 2,923 | 323 | N/A | 560 | N/A |
| 9/30/2014 | 2,957 | 313 | N/A | 527 | N/A |
| 6/30/2014 | 2,953 | 317 | N/A | 506 | N/A |
| 3/31/2014 | 2,949 | 314 | N/A | 446 | N/A |
| 12/31/2013 | 2,951 | 313 | N/A | 418 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: XRAY devrait devenir rentable au cours des 3 prochaines années, ce qui est considéré comme une croissance plus rapide que le taux d'épargne ( 2.6% ).
Bénéfices vs marché: XRAY devrait devenir rentable au cours des 3 prochaines années, ce qui est considéré comme une croissance supérieure à la moyenne du marché.
Croissance élevée des bénéfices: XRAY devrait devenir rentable dans les 3 prochaines années.
Chiffre d'affaires vs marché: Le chiffre d'affaires de XRAY ( 1.2% par an) devrait croître plus lentement que le marché de US ( 9% par an).
Croissance élevée des revenus: Le chiffre d'affaires de XRAY ( 1.2% par an) devrait croître plus lentement que 20% par an.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Le retour sur capitaux propres de XRAY devrait être faible dans 3 ans ( 16.6 %).